Cuvposa glycopyrrolate oral solution regulatory update

FDA approved an NDA from Shionogi for Cuvposa glycopyrrolate to treat chronic severe drooling resulting from neurologic disorders in pediatric patients ages 3-16 years. Shionogi gained the anti-cholin...